BMS joins Octant’s $80M financing and signs on as a drug discovery partner
Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue […]
Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue […]
The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup […]
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 […]
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and […]
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker’s ability to address that market. Zogenix’s […]
Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The […]
The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships […]
Copyright © 2024 | WordPress Theme by MH Themes